164 related articles for article (PubMed ID: 15640267)
1. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.
Stummvoll GH; Aringer M; Smolen JS; Schmaldienst S; Jiménez-Boj E; Hörl WH; Graninger WB; Derfler K
Ann Rheum Dis; 2005 Jul; 64(7):1015-21. PubMed ID: 15640267
[TBL] [Abstract][Full Text] [Related]
2. Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity.
Stummvoll GH; Schmaldienst S; Smolen JS; Derfler K; Biesenbach P
Nephrol Dial Transplant; 2012 Feb; 27(2):618-26. PubMed ID: 21617196
[TBL] [Abstract][Full Text] [Related]
3. Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity.
Biesenbach P; Schmaldienst S; Smolen JS; Hörl WH; Derfler K; Stummvoll GH
Atheroscler Suppl; 2009 Dec; 10(5):114-21. PubMed ID: 20129388
[TBL] [Abstract][Full Text] [Related]
4. Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus.
Huang J; Song G; Yin Z; He W; Zhang L; Kong W; Ye Z
Clin Rheumatol; 2016 Sep; 35(9):2211-8. PubMed ID: 27488202
[TBL] [Abstract][Full Text] [Related]
5. The course of anticardiolipin antibody levels under immunoadsorption therapy.
Hauser AC; Hauser L; Pabinger-Fasching I; Quehenberger P; Derfler K; Hörl WH
Am J Kidney Dis; 2005 Sep; 46(3):446-54. PubMed ID: 16129206
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents.
Karim MY; Alba P; Cuadrado MJ; Abbs IC; D'Cruz DP; Khamashta MA; Hughes GR
Rheumatology (Oxford); 2002 Aug; 41(8):876-82. PubMed ID: 12154204
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study.
Miettunen PM; Pistorio A; Palmisani E; Ravelli A; Silverman E; Oliveira S; Alessio M; Cuttica R; Mihaylova D; Espada G; Pasic S; Insalaco A; Ozen S; Porras O; Sztajnbok F; Lazarevic D; Martini A; Ruperto N;
Ann Rheum Dis; 2013 Sep; 72(9):1503-9. PubMed ID: 23100607
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients.
Pisoni CN; Sanchez FJ; Karim Y; Cuadrado MJ; D'Cruz DP; Abbs IC; Khamasta MA; Hughes GR
J Rheumatol; 2005 Jun; 32(6):1047-52. PubMed ID: 15940766
[TBL] [Abstract][Full Text] [Related]
9. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
10. An unusual case of systemic lupus erythematosus, lupus nephritis, and transient monoclonal gammopathy.
Strobel ES; Fritschka E; Schmitt-Gräff A; Peter HH
Rheumatol Int; 2000; 19(6):235-41. PubMed ID: 11063295
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.
Buratti S; Szer IS; Spencer CH; Bartosh S; Reiff A
J Rheumatol; 2001 Sep; 28(9):2103-8. PubMed ID: 11550982
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.
Castro M; Ugolini-Lopes M; Borba EF; Bonfá E; Seguro LPC
Lupus; 2018 Dec; 27(14):2215-2219. PubMed ID: 30394834
[TBL] [Abstract][Full Text] [Related]
13. Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy.
Stummvoll GH; Aringer M; Jansen M; Smolen JS; Derfler K; Graninger WB
Wien Klin Wochenschr; 2004 Nov; 116(21-22):716-24. PubMed ID: 15628641
[TBL] [Abstract][Full Text] [Related]
14. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
15. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
16. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy.
Karim MY; Pisoni CN; Ferro L; Tungekar MF; Abbs IC; D'Cruz DP; Khamashta MA; Hughes GR
Rheumatology (Oxford); 2005 Oct; 44(10):1317-21. PubMed ID: 16049051
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J
Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacotherapy of SLE].
Nakazawa T; Kumagai S; Kogata Y
Nihon Rinsho; 2005 May; 63 Suppl 5():253-9. PubMed ID: 15954358
[No Abstract] [Full Text] [Related]
19. Update οn the diagnosis and management of systemic lupus erythematosus.
Fanouriakis A; Tziolos N; Bertsias G; Boumpas DT
Ann Rheum Dis; 2021 Jan; 80(1):14-25. PubMed ID: 33051219
[TBL] [Abstract][Full Text] [Related]
20. [Anti-C1q antibodies in patients with systemic lupus erythematosus treated by rituximab].
Tsanyan ME; Torgashina AV; Aleksandrova EN; Soloviev SK; Nasonov EL
Ter Arkh; 2013; 85(5):53-9. PubMed ID: 23819340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
